![](https://static.wixstatic.com/media/a97535_fe22debd629944babf2429a519a6d9b6f000.jpg/v1/fill/w_142,h_80,al_c,q_80,usm_0.66_1.00_0.01,blur_2,enc_auto/a97535_fe22debd629944babf2429a519a6d9b6f000.jpg)
Richner Lab
University of Illinois Chicago
![virus vertical.jpeg](https://static.wixstatic.com/media/a97535_22321d1c7d954710b38753dbfd8b2402~mv2.jpeg/v1/crop/x_359,y_0,w_604,h_1294/fill/w_329,h_566,al_c,q_80,usm_0.66_1.00_0.01,enc_auto/virus%20vertical.jpeg)
Research Overview
The overall goal of the Richner lab is to define the signaling pathways, cytokine networks, and cellular dynamics which lead to a robust adaptive immune response and immunologic memory following viral infection or vaccination. With this information, we can develop novel prophylactics and therapeutics to combat infectious diseases.
​
Increased age is associated with a decrease in the function of the immune response, leading to a greater risk of infectious diseases and reduced vaccine efficacy. One aim of the lab is to uncover the mechanistic underpinning of the defective immune response in aged populations.
​
A second aim of the lab is to develop novel vaccine strategies. Recent technological advances have lead to a number of promising vaccine platforms including antigen-coding mRNA vaccines encpasidated in a lipid nanoparticle. Our lab is working to refine these mRNA-LNP vaccines for use in immunosupressed populations as well as combatting infectious diseases which have proven a significant challenge to traditional vaccine development, such as Dengue virus.